Skip to content

Study · Randomized controlled trial · n = 56 · 1994

12 results

Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery.

Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Páramo JA

Circulation1 Aug 1994Cited by 38 (Europe PMC)

PMID7519132 (opens in a new tab)DOI10.1161/01.cir.90.2.921 (opens in a new tab)PepBankPUB-07519132
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, two DDAVP doses did not significantly reduce blood loss at 12 hours.

    In plain wordsAfter cardiopulmonary bypass, two DDAVP doses did not significantly reduce blood loss compared with no treatment.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood loss at 12 hours
    Study

    n = 56

    Comparator
    No treatment
    Outcome group
    Blood Loss · Cardiovascular
    Studied dose
    Two doses of 0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens.
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
  2. 02HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, two DDAVP doses did not significantly reduce blood loss at 72 hours.

    In plain wordsAfter cardiopulmonary bypass, two DDAVP doses did not significantly reduce blood loss compared with no treatment.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood loss at 72 hours
    Study

    n = 56

    Comparator
    No treatment
    Outcome group
    Blood Loss · Cardiovascular
    Studied dose
    Two doses of 0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens.
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
  3. 03HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, blood loss at 12 hours was greater with two DDAVP doses than with aprotinin.

    In plain wordsAfter cardiopulmonary bypass, two DDAVP doses resulted in more blood loss than aprotinin.

    Peptide
    Desmopressin
    Outcome
    IncreaseBlood loss at 12 hours
    Study

    n = 56

    Comparator
    Aprotinin
    Outcome group
    Blood Loss · Cardiovascular
    Studied dose
    Two doses of 0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens.
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
  4. 04HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, two DDAVP doses did not significantly reduce the amount of blood used.

    In plain wordsAfter cardiopulmonary bypass, two DDAVP doses did not significantly reduce blood replacement compared with no treatment.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood replacement
    Study

    n = 56

    Comparator
    No treatment
    Outcome group
    Blood Transfusion · Cardiovascular
    Studied dose
    Two doses of 0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    A significant reduction in the amount of blood used was observed only in the aprotinin group (P < .01).
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
  5. 05HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, blood loss at 72 hours was greater with two DDAVP doses than with aprotinin.

    In plain wordsAfter cardiopulmonary bypass, two DDAVP doses resulted in more blood loss than aprotinin at 72 hours.

    Peptide
    Desmopressin
    Outcome
    IncreaseBlood loss at 72 hours
    Study

    n = 56

    Comparator
    Aprotinin
    Outcome group
    Blood Loss · Cardiovascular
    Studied dose
    Two doses of 0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens.
    1 context sentence
    Summary · context
    group C (n = 28) received two doses of DDAVP, the first as in group B and an additional dose 6 hours after surgery;
  6. 06HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, one DDAVP dose did not significantly reduce blood loss at 12 hours.

    In plain wordsAfter cardiopulmonary bypass, one DDAVP dose did not significantly reduce blood loss compared with no treatment.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood loss at 12 hours
    Study

    n = 53

    Comparator
    No treatment
    Outcome group
    Blood Loss · Cardiovascular
    Studied dose
    0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens.
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
  7. 07HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, one DDAVP dose did not significantly reduce blood loss at 72 hours.

    In plain wordsAfter cardiopulmonary bypass, one DDAVP dose did not significantly reduce blood loss compared with no treatment.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood loss at 72 hours
    Study

    n = 53

    Comparator
    No treatment
    Outcome group
    Blood Loss · Cardiovascular
    Studied dose
    0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens.
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
  8. 08HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, blood loss at 12 hours was greater with one DDAVP dose than with aprotinin.

    In plain wordsAfter cardiopulmonary bypass, one DDAVP dose resulted in more blood loss than aprotinin.

    Peptide
    Desmopressin
    Outcome
    IncreaseBlood loss at 12 hours
    Study

    n = 53

    Comparator
    Aprotinin
    Outcome group
    Blood Loss · Cardiovascular
    Studied dose
    0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens.
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
  9. 09HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, one DDAVP dose did not significantly reduce the amount of blood used.

    In plain wordsAfter cardiopulmonary bypass, one DDAVP dose did not significantly reduce blood replacement compared with no treatment.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood replacement
    Study

    n = 53

    Comparator
    No treatment
    Outcome group
    Blood Transfusion · Cardiovascular
    Studied dose
    0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    A significant reduction in the amount of blood used was observed only in the aprotinin group (P < .01).
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
  10. 10HumanRandomized controlled trialEfficacy outcome

    After cardiopulmonary bypass, blood loss at 72 hours was greater with one DDAVP dose than with aprotinin.

    In plain wordsAfter cardiopulmonary bypass, one DDAVP dose resulted in more blood loss than aprotinin at 72 hours.

    Peptide
    Desmopressin
    Outcome
    IncreaseBlood loss at 72 hours
    Study

    n = 53

    Comparator
    Aprotinin
    Outcome group
    Blood Loss · Cardiovascular
    Studied dose
    0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens.
    1 context sentence
    Summary · context
    group B (n = 25) received of DDAVP 0.3 micrograms/kg i.v. on completion of CPB;
  11. 11HumanNon-randomized trialSafety outcome

    After cardiopulmonary bypass, no drug-related side effects occurred in patients receiving two DDAVP doses.

    In plain wordsAfter cardiopulmonary bypass, no drug-related side effects occurred with two DDAVP doses.

    Peptide
    Desmopressin
    Outcome
    Not applicableDrug-related side effects
    Study

    n = 28

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Two doses of 0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    No side effects related to the study drugs were observed in any patient.
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
  12. 12HumanNon-randomized trialSafety outcome

    After cardiopulmonary bypass, no drug-related side effects occurred in patients receiving one DDAVP dose.

    In plain wordsAfter cardiopulmonary bypass, no drug-related side effects occurred with one DDAVP dose.

    Peptide
    Desmopressin
    Outcome
    Not applicableDrug-related side effects
    Study

    n = 25

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    0.3 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    No side effects related to the study drugs were observed in any patient.
    1 context sentence
    Summary · context
    This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.